The bridge between European & LatAm ambition and U.S. success
North America, Europe and LatAm are some of the most dynamic technology ecosystems in the world. The companies that capture disproportionate value are increasingly those that operate credibly in both — not just selling across the Atlantic, but building the commercial presence, the investor relationships, and the transaction track record that make them genuine participants in both markets simultaneously. Blueprint exists to make that possible.
The most dangerous mistakes in U.S. market entry are not the obvious ones. They are the structural decisions made at the outset — whose consequences only become apparent a year or two down the line, long after they are cheap to fix.
Most overseas software companies that struggle in the U.S. do not fail because of their product. They fail because they approached the market as outsiders — without the relationships, the cultural fluency, or the operational knowledge that separates a credible U.S. commercial presence from an expensive experiment. The right partners are found through trusted networks built over years in the market, not through search engines. Understanding how U.S. buyers make decisions, how U.S. procurement works, and where European and LatAm assumptions consistently break down requires having operated on both sides.
Blueprint sits at that intersection — Amsterdam and New York, one team, both markets. We bring deep expertise in the technology sector and operate with full alignment to our clients' goals: we are not rewarded for a specific transaction outcome, which means our advice reflects what is right for the company, not what is most convenient for the advisor. The cost of that guidance is almost always a fraction of the cost of fixing avoidable mistakes once they have taken root.
A unique team with the experience to close the gap — not just the deal.
We've spent over five decades combined advising on — and investing in — growth transactions across a wide range of sectors, in both Europe and the U.S. We've worked alongside founders, management teams, and financial sponsors on landmark deals and investments.
Discretion and independence sit at the center of how we work. Every engagement is built around the client's specific situation, not a standard playbook — spanning U.S. market entry, growth financing, and the strategic and financial decisions that come with scaling into a new market. Our advice is our own: unconflicted, senior-delivered, and focused entirely on the outcome that's right for you.
We believe in straightforward, informed advice — the kind that lets you keep running your business while we run the process. Every engagement starts with the U.S. Quick Scan, a direct, no-cost read on whether the timing and market fit are right, before any commitment is made. From there, our senior partners stay hands-on throughout — combining rigorous market intelligence with execution experience — so the process moves with less friction and the outcome is one you actually want.
Blueprint brings U.S. commercial execution and institutional capital relationships together with investment banking rigor — the combination overseas tech companies need to compete in the U.S., not just enter it.
If you're reading this, you're probably already asking the right questions. We'd welcome the chance to work through the answers with you.
Blueprint is an independent advisory firm providing strategic and financial guidance to overseas technology companies seeking to expand, grow and transact in the United States. We combine the rigor of investment banking with the commercial instincts of operators who have built and invested in businesses for decades.
Blueprint conducts certain U.S. M&A advisory activities in reliance on the M&A broker exemption under Section 15(b)(13) of the Securities Exchange Act of 1934, where applicable. Services may not be available in all jurisdictions and are not offered where prohibited by applicable law. Please contact Blueprint to confirm the availability of specific services and the relevant service provider.